In 2024, the drug CONESCO® (INN: ravidasvir ) was registered in the Russian Federation.

CONESCO® is a potent , next-generation pangenotypic NS5A inhibitor. The drug has demonstrated high efficacy compared to other biotarget inhibitors for difficult-to-treat genotypes and pre-existing NS5A mutations, as well as in patients with HCV/HIV coinfection .